IS
iswrit
Community Contributor
Member since 2024
Views44Total number of views
Followers0Total number of followers
Comments0Total number of comments
No bio added yet
No link added
RVPH is poised to have a significant upper hand in the race to combat the rise in the niche mental health market.
With the possibility of being the sole provider to combat skitsophrenia; once they complete phase three they will dominate their market. The drug brilaroxazine that they are working on has proved significant results but the FDA has made its harder for them to release it.Read more
44
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
1users have followed this narrative